Individual Differences in Gut Microbiota: Reconsidering CP101 Efficacy and the Potential Benefits of Bowel Preparation
We read with considerable interest the study, “Safety and tolerability of CP101, a full-spectrum, oral microbiome therapeutic for the prevention of recurrent Clostridioides difficile infection: a phase 2 randomized controlled trial,” by Allegretti et al.1 This study provides valuable insights into the potential of CP101 as a microbiome-based therapy; however, the issue of gut microbiota composition variation warrants further discussion.
